Download PDF
TumorDiagnostik & Therapie 2021; 42(09): 655-661
DOI: 10.1055/a-1631-6377
Schwerpunkt Gastrointestinale Tumoren

Diagnostik und Therapie des Pankreaskarzinoms

Patrick Wenzel
,
Guido von Figura
› Further Information
Also available at
    Permissions and Reprints

Das Pankreaskarzinom bleibt trotz moderner Diagnostik und zielgerichteter Therapien prognostisch sehr ungünstig. Gründe sind das bei Diagnose häufig fortgeschrittene oder metastasierte Stadium und die Tumorbiologie. Der Beitrag gibt einen Überblick über Differenzialdiagnosen, eine sinnvolle Diagnostik, die Verbesserung der operativen Therapie, Möglichkeiten palliativer Chemotherapien sowie die Therapie bei BRCA-Mutation.

Publication History

Article published online:
28 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Zentrum für Krebsregisterdaten und Gesellschaft der Epidemioloschigen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2015/2016. Robert Koch Inst; 2019 12. 1-161 . Im Internet (Stand: 06.12.2020): https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019 / krebs_in_deutschland_2019.pdf?__blob=publicationFile
    PubMedGoogle Scholar
  • 2 Tummers WS, Groen JV, Sibinga Mulder BG. et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg 2019; 106: 1055-1065
    CrossrefPubMedGoogle Scholar
  • 3 Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708
    CrossrefPubMedGoogle Scholar
  • 4 Al-Hawary MM, Francis IR, Chari ST. et al. Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the american pancreatic association. Radiology 2014; 270: 248-260
    CrossrefPubMedGoogle Scholar
  • 5 Guarneri G, Gasparini G, Crippa S. et al. Diagnostic strategy with a solid pancreatic mass. Press Medicale 2019; 48: e125-e145 DOI: 10.1016/j.lpm.2019.02.026.
    CrossrefPubMedGoogle Scholar
  • 6 Oettle H, Neuhaus P, Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA – J Am Med Assoc 2013; 310: 1473-1481
    CrossrefPubMedGoogle Scholar
  • 7 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
    CrossrefPubMedGoogle Scholar
  • 8 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406
    CrossrefPubMedGoogle Scholar
  • 9 Tempero MA, Reni M, Riess H. et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol 2019; 37 (15) 4000
    CrossrefPubMedGoogle Scholar
  • 10 Ahmad SA, Duong M, Sohal DPS. et al. Surgical Outcome Results From SWOG S1505. Ann Surg 2020; 272: 481-486
    CrossrefPubMedGoogle Scholar
  • 11 Suker M, Beumer BR, Sadot E. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17: 801-810
    CrossrefPubMedGoogle Scholar
  • 12 Philip PA, Lacy J, Portales F. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020; 5: 285-294
    CrossrefPubMedGoogle Scholar
  • 13 Kunzmann V, Algül H, Goekkurt E. et al. Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial. Ann Oncol 2019; 30: v253
    CrossrefPubMedGoogle Scholar
  • 14 Picozzi V, Alseidi A, Winter J. et al. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO open 2020; 5: e000668
    CrossrefPubMedGoogle Scholar
  • 15 Burris HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413
    CrossrefPubMedGoogle Scholar
  • 16 Moore MJ, Goldstein D, Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
    CrossrefPubMedGoogle Scholar
  • 17 Haas M, Siveke JT, Schenk M. et al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Eur J Cancer 2018; 94: 95-103
    CrossrefPubMedGoogle Scholar
  • 18 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
    CrossrefPubMedGoogle Scholar
  • 19 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
    CrossrefPubMedGoogle Scholar
  • 20 Wang-Gillam A, Li CP, Bodoky G. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545-557
    CrossrefPubMedGoogle Scholar
  • 21 Van Cutsem E, Tempero MA, Sigal D. et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020; 38 (27) 3185-3194
    CrossrefPubMedGoogle Scholar
  • 22 Ramanathan RK, McDonough SL, Philip PA. et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol 2019; 37: 1062
    CrossrefPubMedGoogle Scholar
  • 23 Renouf DJ, Knox JJ, Kavan P. et al. LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcin. Ann Oncol 2020; 31: S1195
    CrossrefPubMedGoogle Scholar
  • 24 Bailey P, Chang DK, Nones K. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52
    CrossrefPubMedGoogle Scholar
  • 25 Golan T, Hammel P, Reni M. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317-327
    CrossrefPubMedGoogle Scholar
  • 26 Ducreux M, Cuhna AS, Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v56-v68
    CrossrefPubMedGoogle Scholar
  • 27 Khorana AA, McKernin SE, Berlin J. et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol 2019; 37: 2082-2088
    CrossrefPubMedGoogle Scholar
  • 28 Colombo N, Dubot C, Lorusso D. et al. Annals of Oncology 2021; 32 (Suppl. 05) S1283-S1346 DOI: 10.1016/annonc/annonc741.
    CrossrefPubMed
  • 29 Oettle H, Riess H, Stieler JM. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-2429
    CrossrefPubMedGoogle Scholar